STOCK TITAN
  1. Home
  2. Sec-filings
  3. CADL
  4. [Form 4] Candel Therapeutics, Inc. Insider Trading Activity

Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Candel Therapeutics director Paul B. Manning received a grant of stock options as compensation. He was awarded options to buy 2,199 shares of common stock at an exercise price of $10.30 per share. The award replaces normal quarterly cash payments and is fully vested at the time of grant, leaving him with 2,199 derivative securities after this transaction.

Positive

  • None.

Negative

  • None.
Insider Manning Paul B
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,199 $8.639 $19K
Holdings After Transaction: Stock Option (Right to Buy) — 2,199 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 2,199 options Stock Option (Right to Buy) grant to director
Exercise price $10.30 per share Exercise price for granted stock options
Post-grant derivative holdings 2,199 derivative securities Total options held after this grant
Grant date June 30, 2026 Option award transaction date
Expiration date June 30, 2036 Option expiration if not exercised
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "10.3000" as the exercise price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"The underlying award quantity is fully vested at time of grant."
in lieu of normal quarterly cash payments financial
"This award has been granted in lieu of normal quarterly cash payments."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Manning Paul B
(Last)(First)(Middle)
C/O CANDEL THERAPEUTICS, INC.
117 KENDRICK ST., SUITE 450
(Street)
NEEDHAM MASSACHUSETTS 02494
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$10.306/30/2026A2,19907/01/2026(1)06/30/2036Common Stock2,199$8.6392,199D
Explanation of Responses:
1. This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.
/s/ Charles Schoch, as Attorney-In-Fact for Paul B. Manning07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Candel Therapeutics (CADL) director Paul B. Manning report in this Form 4?

Paul B. Manning reported receiving a grant of stock options for 2,199 shares of Candel Therapeutics common stock. These options are a form of equity compensation and are documented as an acquisition transaction on the Form 4.

How many Candel Therapeutics (CADL) stock options did Paul B. Manning receive?

He received stock options covering 2,199 shares of Candel Therapeutics common stock. This grant increases his derivative holdings by that amount, reflecting additional potential future ownership if the options are exercised.

What is the exercise price of Paul B. Manning’s Candel Therapeutics (CADL) options?

The options have an exercise price of $10.30 per share. This means Manning can purchase Candel Therapeutics common stock at $10.30 per share if he exercises the options before they expire.

When do Paul B. Manning’s Candel Therapeutics (CADL) stock options vest and expire?

The award is fully vested at the time of grant, according to the footnote. The options are scheduled to expire on June 30, 2036 if they are not exercised by that expiration date.

Why was Paul B. Manning granted stock options instead of cash by Candel Therapeutics (CADL)?

The footnote explains the award was granted in lieu of normal quarterly cash payments. This indicates Candel Therapeutics chose to compensate Manning with equity-based awards rather than customary cash compensation for that period.

How many derivative securities does Paul B. Manning hold in Candel Therapeutics (CADL) after this grant?

Following this transaction, Manning holds 2,199 derivative securities related to Candel Therapeutics. These represent the stock options granted in this filing and show his post-transaction derivative position from this award.